The risk of dying from the most common form of primary liver cancer is about 30% higher for patients with low household ...

There is no standard of care for fibrolamellar liver cancer, no targeted therapies. But that may be changing, thanks to ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Among patients with hepatocellular carcinoma, MAFLD was not an independent predictor for overall survival or progression-free ...

Objective To evaluate the relationship between the absorbed dose and radiological response in patients with hepatocellular carcinoma undergoing resin microsphere radioembolization to enhance treatment ...

therapy has changed the paradigm of hepatocellular carcinoma (HCC) treatment. However, the response rate of ICB therapy remains low (below 20%), which is possibly due to heterogeneity of HCC cells and ...

6.4 The pro-tumor role of MNDA in hepatocellular carcinoma MNDA, predominantly expressed in tumor-associated M2 macrophages, critically orchestrates the crosstalk between M2 macrophages and HCC cells ...

Introduction: Breast cancer (BRCA) is a phenotypically and functionally heterogeneous disease. New biomarkers or therapeutic targets must be discovered to improve treatment effects. The polymeric ...

1Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.